Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages - Institut Pasteur Access content directly
Journal Articles iScience Year : 2023

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages

Franck Touret
  • Function : Correspondent author
  • PersonId : 1066975

Connectez-vous pour contacter l'auteur

Abstract

The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous appearance of multiple subvariants originating from BA.2, BA.4, and BA.5 Omicron sub-lineages. They harbor a specific set of mutations in the spike that can make them more evasive to therapeutic monoclonal antibodies. In this study, we compared the neutralizing potential of monoclonal antibodies against the Omicron BA.2.75.2, BQ.1, BQ.1.1, and XBB variants, with a pre-Omicron Delta variant as a reference. Sotrovimab retains some activity against BA.2.75.2, BQ.1, and XBB as it did against BA.2/BA.5, but is less active against BQ.1.1. Within the Evusheld/AZD7442 cocktail, Cilgavimab lost all activity against all subvariants studied, resulting in loss of Evusheld activity. Finally, Bebtelovimab, while still active against BA.2.75, also lost all neutralizing activity against BQ.1, BQ.1.1, and XBB variants.
Fichier principal
Vignette du fichier
1-s2.0-S258900422300490X-main.pdf (1.33 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY NC ND - Attribution - NonCommercial - NoDerivatives

Dates and versions

pasteur-04072734 , version 1 (18-04-2023)

Licence

Attribution - NonCommercial - NoDerivatives

Identifiers

Cite

Franck Touret, Emilie Giraud, Jérôme Bourret, Flora Donati, Jaouen Tran-Rajau, et al.. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages. iScience, 2023, 26 (4), pp.106413. ⟨10.1016/j.isci.2023.106413⟩. ⟨pasteur-04072734⟩
100 View
10 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More